SCHEMBL21058771

SCHEMBL21058771

COc1ccc(-c2cc(Cl)nc(Cl)n2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
ALDH1A1 P00352 8/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
KDM4E B2RXH2 6/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
CYP17A1 P05093 1/20 0.43
SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21058420 0.88 MEN1 (0.55) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL2175274 0.86 MEN1 (0.72) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL31391067 0.81 ALDH1A1 (0.52) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL21058802 0.80 ALDH1A1 (0.42) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL1742298 0.77 ALDH1A1 (0.51) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL3451541 0.76 KDM4E (0.67) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL908228 0.76 KMO (0.47) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3995066 0.76 ALDH1A1 (0.60) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL908398 0.75 MEN1 (0.52) MEN1KMT2AL3MBTL1ALDH1A1NPC1
SCHEMBL9464193 0.74 CYP17A1 (0.61) MEN1KMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190185456-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185456-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF POLRMT, EIF2AK2, POLM MEN1 4473/4885KMT2A 1637/4885L3MBTL1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.